Advanced search
Start date
Betweenand


Association Between Papillary Thyroid Cancer and Primary Aldosteronism in Individuals With Hypertension

Full text
Author(s):
Show less -
Maciel, Ana Alice W. ; Danilovic, Debora L. S. ; Soares, Ibere C. ; Freitas, Thais C. ; Okubo, Jessica ; Fagundes, Gustavo F. C. ; Freitas-Castro, Felipe ; Santana, Lucas S. ; Guimaraes, Augusto G. ; Calsavara, Vinicius F. ; Ledesma, Felipe L. ; Castroneves, Luciana A. ; Coelho, Fernando M. A. ; Srougi, Victor ; Tanno, Fabio Y. ; Chambo, Jose L. ; Carnevale, Francisco C. ; Silveira, Joao, V ; Consolim-Colombo, Fernanda M. ; Bortolotto, Luiz A. ; Brito, Luciana P. ; Fragoso, Maria Candida B., V ; Drager, Luciano F. ; Gomez-Sanchez, Celso E. ; Latronico, Ana Claudia ; Mendonca, Berenice B. ; Hoff, Ana O. ; Almeida, Madson Q.
Total Authors: 28
Document type: Journal article
Source: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. N/A, p. 12-pg., 2024-09-30.
Abstract

Context: Aldosterone excess chronically induces oxidative stress and cell proliferation. Previously, a single study investigated primary aldosteronism (PA) in patients with papillary thyroid cancer (PTC), albeit without a matched control group. Objective: We conducted a propensity score-matched, case-control study to investigate the association between PA and PTC in individuals with arterial hypertension (HT). Methods: PA was investigated in 137 patients with PTC and HT. The control group included 137 (1:1) age-, sex-, and body mass index-matched individuals with HT. We conducted a secondary analysis in which controls were also matched according to HT stage. Results: The prevalence of PA was 29.20% (95% CI, 21.91%-37.68%) in the PTC group and 20.44% (95% CI, 14.22%-28.35%) in the controls not matched by HT stage (P = .093). Although the PA prevalence was similar in both groups, the frequency of severe HT (stage III or resistant) was significantly lower in the PTC group (23%) compared to the HT controls (73%; P < .001). After matching the controls by HT stage, the prevalence of PA in the PTC group was significantly higher compared to the hypertensive controls (9.56%; 95% CI, 5.39%-16.1%; P < .0001). In the multivariable analysis, PTC was independently associated with PA both in unmatched HT individuals (odds ratio [OR] 4.74; 95% CI, 2.26-10.55; P < .001) and in those matched by HT stage (OR 5.88; 95% CI, 2.79-13.37; P < .001). Conclusion: PTC was an independent variable associated with a diagnosis of PA in HT individuals. Therefore, we propose the association between PTC and HT as a new recommendation for PA screening regardless of HT severity. (AU)

FAPESP's process: 21/10101-5 - Investigation of novel genetic alterations associated with the pathogenesis of Aldosteronomas by exome sequencing
Grantee:Augusto Garcia Guimarães
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 21/11240-9 - Whole exome sequencing for the investigation of novel genetic causes of metastatic Pheochromocytomas and Paragangliomas
Grantee:Felipe Freitas de Castro
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 21/10363-0 - Whole exome sequencing for investigation of novel genetic causes of primary Aldosteronism caused by bilateral adrenal hyperplasia
Grantee:Lucas Santos de Santana
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 19/15873-6 - Investigation of new genetic, clinical and pathological aspects of endocrine arterial hypertension
Grantee:Madson Queiroz Almeida
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 21/09879-1 - Clinical and genetic investigation of the association between Primary Aldosteronism and Papillary Thyroid Cancer
Grantee:Ana Alice Wolf Maciel
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)